GEORGE I GORODESKI, MD
Medical Practice at Bridgeton Dr, Cleveland, OH

2010019, Aug 5, 2010

Mar 13, 2008

12/450124

George Gorodeski - Beachwood OH, US
Judith Potashkin - gurnee IL, US
Bentley Cheatham - Durham NC, US

UNIVERSITY OF CLEVELAND - Cleveland OH
ROSILAND FRANKLIN UNIVERSITY OF MEDICINE AND SCIEN - North Chicago IL
RIBONOMICS, INC. - Durham NC

C12Q 1/68, C07H 21/02, G01N 33/567

435 6, 536 231, 435 721

A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2XmRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

2007028, Dec 13, 2007

Jun 7, 2007

11/810916

George Gorodeski - Beachwood OH, US
Richard Domanik - Libertyville IL, US

C12Q 1/68, G01N 33/574, A61M 31/00

435006000, 435007230, 604500000

The present application discloses methods and tools for collecting cells to screen for disease, such as cancer. In one method of screening for a disease a flush fluid is injected into a human cavity, such as a uterus. The flush fluid and entrained cells from the cavity are withdrawn from the cavity and collected. The intermixed cells may be separated from the fluid and analyzed to determine whether the cells have a characteristic that is indicative of the presence of a disease. One tool for applying and withdrawing a fluid includes a nozzle, a screening fluid supply and fluid withdrawal mechanism. The nozzle includes an inlet port and an outlet port. The screening fluid supply supplies a screening fluid through the outlet port. The withdrawal mechanism withdraws fluid through the outlet port.

2007013, Jun 14, 2007

Oct 21, 2004

10/576214

George Gorodeski - Beachwood OH, US

A61K 9/22

604892100

A method and apparatus for applying medication to internal human tissue. One drug delivery member () for applying medication () to internal human tissue includes a medication impermeable barrier () and a medication-carrying matrix (). The medication impermeable barrier is shaped to conform to a contour of the internal tissue. The medication-carrying matrix releases the medication to the human tissue upon being applied to the internal human tissue. The matrix may be adapted to adhere to the internal human tissue.

2007002, Jan 25, 2007

Jun 2, 2006

11/446420

George Gorodeski - Beachwood OH, US
Ying-Hong Feng - Germantown MD, US
Xin Li - Solon OH, US

G01N 33/574, C07H 21/04, C12P 21/06, C07K 16/30, C07K 14/82

435007230, 435069100, 435320100, 435325000, 530350000, 530388800, 536023500

Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2Xprotein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2Xin cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2Xin cells are described.

8518652, Aug 27, 2013

Apr 28, 2010

12/769433

George Gorodeski - Beachwood OH, US
Ying-Hong Feng - Germantown MD, US
Xin Li - Solon OH, US

Uniformed Services University of the Health Sciences, an Institution of Higher Learning within the Department of Defense. - Washington DC
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD

G01N 33/53, C07K 16/18

435 71, 5303879

Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2Xprotein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2Xin cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2Xin cells are described.

8314068, Nov 20, 2012

Sep 4, 2009

12/554444

George Gorodeski - Beachwood OH, US
Wen Fu - Broadview Ht OH, US

University Hospitals of Cleveland - Cleveland OH

A61P 35/00, C07K 14/705

514 189, 514 192, 514 193

The present invention demonstrates that P2Xreceptor induced apoptosis may be specific for cancerous cells. Treatment with the P2Xligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of developed papillomas and stimulated apoptosis in keratinocytes outgrowing at the base of developed papillomas. These data show that (a) P2Xregulates apoptosis of epidermal cells; (b) in vivo, local administration of a drug that activates the P2Xreceptor can inhibit development and progression of epidermal premalignant lesions.

2014003, Feb 6, 2014

Sep 25, 2012

13/626154

George Gorodeski - Beachwood OH, US
Wen Fu - Broadview OH, US

A61K 31/7076, A61K 38/19

424 851, 514 47

The present invention demonstrates that P2Xreceptor induced apoptosis may be specific for cancerous cells. Treatment with the P2Xligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of developed papillomas and stimulated apoptosis in keratinocytes outgrowing at the base of developed papillomas. These data show that (a) P2Xregulates apoptosis of epidermal cells; (b) in vivo, local administration of a drug that activates the P2Xreceptor can inhibit development and progression of epidermal premalignant lesions.

2008007, Mar 20, 2008

Aug 31, 2005

11/574279

George Gorodeski - Beachwood OH, US
Chung Liu - Cleveland Heights OH, US

A61B 10/00

600551000

A method of diagnosing ovulation in a female mammal comprises measuring the pH of the ectocervix of the female mammal and comparing the pH measured of the ectocervix to a reference value.